ORLANDO, Fla.--(BUSINESS WIRE)--Trabedersen (AP 12009), a first in class investigational therapy for the treatment of aggressive tumors, showed a good safety and tolerability profile and encouraging survival data in patients with pancreatic carcinoma, malignant melanoma and colorectal carcinoma. Data from a Phase I/II study, announced at the American Society of Clinical Oncology (ASCO) 2009, will lead to further clinical studies. Currently an additional 24 patients with pancreatic carcinoma or malignant melanoma are being recruited to confirm the promising efficacy and safety results with trabedersen. (Abstract 4619)
